MSON - Misonix's TheraSkin to be covered by U.S. commercial payer
Misonix ([[MSON]] +0.4%) has announced that the second largest U.S. Commercial payer will now cover TheraSkin, cellular and tissue-based treatment for all lower extremity dermal wounds, including venous leg ulcers and diabetic foot ulcers.The company says that with this new coverage, it can now have additional 32M covered lives.